Table 2. Cox regression analysis of overall survival in locally advanced esophageal cancer patients (n = 33).
| Characteristics | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Age (yr) | 0.551 | |||||
| ≤ 60 | 1 | |||||
| > 60 | 1.34 | 0.509-3.545 | ||||
| Gender | 0.287 | |||||
| Female | 1 | |||||
| Male | 2.99 | 0.399-22.407 | ||||
| Response to radiotherapy | 0.221 | |||||
| CR/PR | 1 | |||||
| SD/PD | 1.96 | 0.667-5.753 | ||||
| LDH | 0.085 | |||||
| ≤ 410.0 | 1 | |||||
| > 410.0 | 2.32 | 0.890-6.043 | ||||
| Hb | 0.158 | |||||
| ≤ 13 | 1 | |||||
| > 13 | 2.09 | 0.751-5.827 | ||||
| Differentiation | 0.794 | |||||
| Well | 1 | |||||
| Moderate | 0.92 | 0.251-3.337 | ||||
| Poorly | 0.47 | 0.049-4.511 | ||||
| Tumor length (cm) | 0.809 | |||||
| ≤ 6 cm | 1 | |||||
| > 6 cm | 1.41 | 0.085-23.573 | ||||
| TNM stage | 0.990 | |||||
| II | 1 | |||||
| III | 1.01 | 0.233-4.380 | ||||
| Chemotherapy regimen | 0.013* | 0.001* | ||||
| Single | 1 | 1 | ||||
| Combination | 3.41 | 1.295-8.959 | 6.76 | 2.149-21.248 | ||
| SUVpeak | 0.821 | |||||
| ≤ 11.0 | 1 | |||||
| > 11.0 | 1.11 | 0.450-2.736 | ||||
| SUVmean | 0.805 | |||||
| ≤ 5.70 | 1 | |||||
| > 5.70 | 1.12 | 0.454-2.767 | ||||
| SUVmax | 0.854 | |||||
| ≤ 13.30 | 1 | |||||
| > 13.30 | 0.92 | 0.373-2.264 | ||||
| MTV | 0.061 | |||||
| ≤ 44.70 | 1 | |||||
| > 44.70 | 2.34 | 0.962-5.683 | ||||
| TLG | 0.007* | 0.002* | ||||
| ≤ 232.98 | 1 | 1 | ||||
| > 232.98 | 4.69 | 1.540-14.281 | 7.12 | 2.038-24.857 | ||
*Statistically significant. HR, hazard ratio; CI, confidence interval; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; LDH, lactate dehydrogenase; Hb, haemoglobin; MTV, metabolic tumor volume; TLG, tumor glycolysis.